Backlinks
| Referring page | DR | Ref. domains | Linked domains | Anchor and target URL |
|---|---|---|---|---|
|
The Psychedelic Syndicate: Part 1
https://www.psymposia.com/magazine/psychedelic-syndicate-part-1-silicon-valley-maps-lykos-mdma-fda-billionaires
psymposia.com
|
66 | 42 | 358 |
uncollected safety data
https://www.biopharmadive.com/news/lykos-fda-advisory-committee-mdma-adcomm-ptsd/717646
DOFOLLOW
|
|
FDA starts device sterilization pilot program to help industry adapt to EtO e...
https://www.medtechdive.com/news/fda-device-sterilization-pilot-program-eto-radiation/647418?utm_campaign=Issue: 2023-04-12 MedTech Dive [issue:49580]&utm_medium=email&utm_source=Sailthru&utm_term=MedTech Dive
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Developers delay billions in projects amid mounting uncertainty | Constructio...
https://www.constructiondive.com/news/developers-delay-billions-projects-uncertainty/745939
constructiondive.com
|
78 | 632 | 1,304 |
$23 billion over five years
https://www.biopharmadive.com/news/novartis-23-billion-us-manufacturing-new-drug-plants/745076
DOFOLLOW
|
|
Senate sets date to vet RFK Jr.’s nomination to lead HHS | MedTech Dive
https://www.medtechdive.com/news/rfk-kennedy-hhs-senate-confirmation-hearing/738128
medtechdive.com
|
73 | 215 | 717 |
largely downplayed
https://www.biopharmadive.com/news/jpm25-the-fdas-future-abbvies-second-thoughts-and-lillys-lesson/737487
DOFOLLOW
|
|
Senate sets date to vet RFK Jr.’s nomination to lead HHS | MedTech Dive
https://www.medtechdive.com/news/rfk-kennedy-hhs-senate-confirmation-hearing/738128
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Senate sets date to vet RFK Jr.’s nomination to lead HHS | MedTech Dive
https://www.medtechdive.com/news/rfk-kennedy-hhs-senate-confirmation-hearing/738128
medtechdive.com
|
73 | 215 | 717 |
“go wild”
https://www.biopharmadive.com/news/trump-name-rfk-kennedy-hhs-secretary-nomination/733013
DOFOLLOW
|
|
Senate sets date to vet RFK Jr.’s nomination to lead HHS | MedTech Dive
https://www.medtechdive.com/news/rfk-kennedy-hhs-senate-confirmation-hearing/738128
medtechdive.com
|
73 | 215 | 717 |
top FDA officials
https://www.biopharmadive.com/news/fda-patrizia-cavazzoni-retire-cder-trump-administration/737014
DOFOLLOW
|
|
J&J starts IVL trial in ‘difficult-to-cross’ coronary arteries | MedTech Dive
https://www.medtechdive.com/news/jnj-ivl-shockwave-javelin/744696
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Biotech & Pharma Updates | November 3 - 4, 2024
https://tldrbio.tech/p/biotech-pharma-updates-november-3-4-2024
tldrbio.tech
|
7 | 1 | 299 |
Read more
https://www.biopharmadive.com/news/novo-ascendis-glp-1-obesity-diabetes-deal/731871?amp;utm_campaign=biotech-pharma-updates-november-3-4-2024&utm_medium=referral&utm_source=tldrbio.tech
DOFOLLOW
|
|
Biotech & Pharma Updates | November 3 - 4, 2024
https://tldrbio.tech/p/biotech-pharma-updates-november-3-4-2024
tldrbio.tech
|
7 | 1 | 299 |
promising Ph1 data for its obesity pill
https://www.biopharmadive.com/news/viking-obesity-drug-results-vk2735-oral/731862?amp;utm_campaign=biotech-pharma-updates-november-3-4-2024&utm_medium=referral&utm_source=tldrbio.tech
DOFOLLOW
|
|
Biotech & Pharma Updates | November 3 - 4, 2024
https://tldrbio.tech/p/biotech-pharma-updates-november-3-4-2024
tldrbio.tech
|
7 | 1 | 299 |
Read more
https://www.biopharmadive.com/news/neurogene-pipe-financing-rett-syndrome/731886?amp;utm_campaign=biotech-pharma-updates-november-3-4-2024&utm_medium=referral&utm_source=tldrbio.tech
DOFOLLOW
|
|
FDA rejects Lykos MDMA study: Why we support this decision - Pharmaceutical I...
https://bve.vc/fda-rejects-lykos-mdma-study-why-we-support-this-decision
bve.vc
|
— | 0 | 20 |
In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD
https://www.biopharmadive.com/news/fda-mdma-therapy-rejection-psychedelics-lykos/723869
DOFOLLOW
|
|
Edwards gets FDA nod for mitral regurgitation treatment | MedTech Dive
https://www.medtechdive.com/news/edwards-fda-approval-pascal-precision/632056
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Biogen plots new global headquarters in Kendall Square | PharmaVoice
https://www.pharmavoice.com/news/biogen-global-headquarters-kendall-square-boston-biotech/743389
pharmavoice.com
|
70 | 151 | 621 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Biogen plots new global headquarters in Kendall Square | PharmaVoice
https://www.pharmavoice.com/news/biogen-global-headquarters-kendall-square-boston-biotech/743389
pharmavoice.com
|
70 | 151 | 621 |
Jacob Bell's headshot
https://www.biopharmadive.com/editors/jbell
DOFOLLOW
|
|
Tandem reports 224 injuries related to faulty insulin pump app | MedTech Dive
https://www.medtechdive.com/news/tandem-224-injuries-recall-iphone-app-insulin-pump/715613
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Profiles | PharmaVoice
https://www.pharmavoice.com/profiles?page=2
pharmavoice.com
|
70 | 151 | 621 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Merck buys rights to heart disease drug - Search News
https://www4.bing.com/news/topicview?filters=tnTID="EB389582-7531-4eae-9023-0648BA94E006" tnVersion="6082703" Segment="popularnow.carousel" tnCol="13" tnOrder="3c9ee85c-e70a-44de-9376-b00800e31941"&form=NWBTTC&nvaug=[NewsVertical topicviewtype="2"]&q=Merck buys rights to heart disease drug
www4.bing.com
|
14 | 21 | 2,334 |
(no anchor)
https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287
DOFOLLOW
|
|
FDA chief warns of supply 'pressure' on reagents for coronavirus tests | MedT...
https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-coronavirus-tests/573999
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
When a Health Care Business Model Disruption is Self-Destructive - Health Wor...
https://www.healthworkscollective.com/when-disruption-not-really-self-destructive
healthworkscollective.com
|
55 | 83 | 1,774 |
seeing now
http://www.biopharmadive.com/news/what-in-the-world-is-going-on-at-valeant-a-guide-to-what-we-know-so-far/407799
DOFOLLOW
|
|
TuringDB and CiteAb Announce a Strategic Partnership to Improve Reagent Ident...
https://blog.citeab.com/turingdb-citeab-strategic-partnership-to-improve-reagent-identification
blog.citeab.com
|
45 | 5 | 44 |
BioPharma Dive
https://www.biopharmadive.com/press-release/20260116-turingdb-and-citeab-announce-a-strategic-partnership-to-improve-reagent-ide-1
DOFOLLOW
|
|
Breast cancer AI company iCAD lays off workers, names new CEO | MedTech Dive
https://www.medtechdive.com/news/iCAD-AI-layoffs-new-ceo/646300
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
offload the drug
https://www.biopharmadive.com/news/biomarin-divest-roctavian-hemophilia-gene-therapy/803931
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
offload the drug
https://www.biopharmadive.com/news/biomarin-divest-roctavian-hemophilia-gene-therapy/803931
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
pulled
https://www.biopharmadive.com/news/pfizer-beqvez-hemophilia-halt-sales-gene-therapy/740590
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
pulled
https://www.biopharmadive.com/news/pfizer-beqvez-hemophilia-halt-sales-gene-therapy/740590
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
of $2.2 billion
https://www.biopharmadive.com/news/biomarin-roctavian-sales-hemophilia-gene-therapy/708321
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
of $2.2 billion
https://www.biopharmadive.com/news/biomarin-roctavian-sales-hemophilia-gene-therapy/708321
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
$47,400 annual price tag
https://www.biopharmadive.com/news/madrigal-rezdiffra-mash-drug-price-launch-plans/710404
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
$47,400 annual price tag
https://www.biopharmadive.com/news/madrigal-rezdiffra-mash-drug-price-launch-plans/710404
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
FDA approval for MASH in August
https://www.biopharmadive.com/news/novo-wegovy-mash-fda-approval-rezdiffra-madrigal/757853
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
FDA approval for MASH in August
https://www.biopharmadive.com/news/novo-wegovy-mash-fda-approval-rezdiffra-madrigal/757853
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
efimosfermin
https://www.biopharmadive.com/news/gsk-boston-pharmaceuticals-liver-drug/748099
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
efimosfermin
https://www.biopharmadive.com/news/gsk-boston-pharmaceuticals-liver-drug/748099
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
Roche deal
https://www.biopharmadive.com/news/roche-89bio-deal-acquire-mash-drug-fgf21-pegozafermin/760483
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
Roche deal
https://www.biopharmadive.com/news/roche-89bio-deal-acquire-mash-drug-fgf21-pegozafermin/760483
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
consistently beat expectations
https://www.biopharmadive.com/news/madrigal-rezdiffra-mash-first-quarter-earnings-sales/746850
DOFOLLOW
|
|
Commercialization, marketing and social media | PharmaVoice
https://www.pharmavoice.com/trendline/commercialization-marketing-social-media/480?utm_campaign=EVERSANA&utm_medium=Library&utm_source=PV
pharmavoice.com
|
70 | 151 | 621 |
consistently beat expectations
https://www.biopharmadive.com/news/madrigal-rezdiffra-mash-first-quarter-earnings-sales/746850
DOFOLLOW
|
|
11 key moments in Philips’ massive recall of respiratory devices | MedTech Dive
https://www.medtechdive.com/news/philips-respironics-recall-roundup-10-sleep-apnea/698084
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Biotech & Pharma Updates | July 28 - 29, 2024
https://tldrbio.tech/p/tldr-biotech-pharma-updates-july-28-29-2024
tldrbio.tech
|
7 | 1 | 299 |
Read more
https://www.biopharmadive.com/news/newamsterdam-obicetrapib-hefh-brooklyn-study-results-cetp/722608?amp;utm_campaign=biotech-pharma-updates-july-28-29-2024&utm_medium=referral&utm_source=tldrbio.tech
DOFOLLOW
|
|
Biotech & Pharma Updates | July 28 - 29, 2024
https://tldrbio.tech/p/tldr-biotech-pharma-updates-july-28-29-2024
tldrbio.tech
|
7 | 1 | 299 |
Read more
https://www.biopharmadive.com/news/boehringer-ingelheim-nerio-acquire-checkpoint-inhibitor/722623?amp;utm_campaign=biotech-pharma-updates-july-28-29-2024&utm_medium=referral&utm_source=tldrbio.tech
DOFOLLOW
|
|
Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Pr...
https://www.sciltp.com/journals/ijddp/articles/2504000410
sciltp.com
|
61 | 20 | 262 |
https://www.biopharmadive.com/news/pfizer-duchenne-phase-3-study-reopen/618642/
https://www.biopharmadive.com/news/pfizer-duchenne-phase-3-study-reopen/618642
DOFOLLOW
|
|
Microbot receives 510(k) clearance for endovascular robot | MedTech Dive
https://www.medtechdive.com/news/microbot-510k-clearance-liberty-endovascular-robot/759573
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
TrialX Selected by ALK Positive, Inc. to Power it’s First AI-Assisted Clinica...
https://www.pharmavoice.com/press-release/20251119-trialx-selected-by-alk-positive-inc-to-power-its-first-ai-assisted-clini
pharmavoice.com
|
70 | 151 | 621 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Exact Sciences founders raise $56M for new liquid biopsy venture | MedTech Dive
https://www.medtechdive.com/news/haystack-oncology-funding-exact-sciences-founders/636822
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
https://www.facebook.com/SterilAirUVReviews/ – General Discussion – usasupple...
usasupplementreviews.com
|
46 | 19 | 7 |
https://www.biopharmadive.com/press-release/editor/aa1cc0b8-cf56-4a4c-b02b-033fd8e1ca6b/review
NOFOLLOW
|
|
FDA labels Celltrion's latest recall of 310,000 COVID-19 tests as a Class I e...
https://www.medtechdive.com/news/celltrion-recall-covid-tests-class-i/622999
medtechdive.com
|
73 | 215 | 717 |
BioPharma Dive
https://www.biopharmadive.com/
DOFOLLOW
|
|
Innovations Advanced by M&A: A Cure for Inherited Blindness - Partnership for...
pulseforinnovation.org
|
12 | 2 | 60 |
45 companies
DOFOLLOW
|
Frequently Asked Questions
How many backlinks does biopharmadive.com have?
The backlinks page for biopharmadive.com shows all individual inbound links discovered in our crawl of the web. Each backlink represents a hyperlink on another website that points to a page on biopharmadive.com. Use the filters to narrow results by dofollow/nofollow status, domain rating, or anchor text.
What is a backlink?
A backlink is a hyperlink on one website that points to a page on a different website. Backlinks are one of the most important ranking factors in search engine algorithms because they act as votes of confidence from other sites. The more high-quality backlinks a domain has, the more authority search engines assign to it.
Are the backlinks to biopharmadive.com dofollow or nofollow?
Backlinks to biopharmadive.com include both dofollow and nofollow links. Dofollow links pass link equity (ranking power) to the target site, while nofollow links include a rel="nofollow" attribute that tells search engines not to pass authority. Both types contribute to a natural backlink profile, but dofollow links carry more SEO weight. You can filter by link type using the rel filter above the table.
How often is backlink data updated?
Backlink data is updated monthly when our web crawler completes a new cycle. Our pipeline processes billions of web pages to discover new backlinks, track lost links, and update domain authority scores. The freshness of data depends on when our crawler last visited the referring pages.